Detalhe da pesquisa
1.
Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology.
Bioorg Med Chem Lett
; 28(11): 2029-2034, 2018 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29748051
2.
Kibdelomycin is a bactericidal broad-spectrum aerobic antibacterial agent.
Antimicrob Agents Chemother
; 59(6): 3474-81, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25845866
3.
Structure Guided Discovery of Novel Pan Metallo-ß-Lactamase Inhibitors with Improved Gram-Negative Bacterial Cell Penetration.
J Med Chem
; 67(5): 3400-3418, 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38387069
4.
Rapid Evolution of a Fragment-like Molecule to Pan-Metallo-Beta-Lactamase Inhibitors: Initial Leads toward Clinical Candidates.
J Med Chem
; 65(24): 16234-16251, 2022 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36475645
5.
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
JCI Insight
; 3(4)2018 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29467321
6.
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology.
ACS Med Chem Lett
; 9(7): 761-767, 2018 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30034615
7.
Dissecting Therapeutic Resistance to ERK Inhibition.
Mol Cancer Ther
; 15(4): 548-59, 2016 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26832798
8.
Analysis of the ERK1,2 transcriptome in mammary epithelial cells.
Biochem J
; 381(Pt 3): 635-44, 2004 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15109307
9.
Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase.
J Med Chem
; 57(21): 8817-26, 2014 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-25313996
10.
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
Cancer Discov
; 3(7): 742-50, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23614898